ECO ANIMAL HEALTH GROUP PLC

AGM Information • Oct 22, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Eco Animal Health Group Plc

(“ECO” or the “Company”)

Result of General Meeting

22 October 2013

The Company announces that at its General Meeting held today, all resolutions put to shareholders were duly passed.

Accordingly, 7,053,385 new ordinary shares are expected to be admitted to trading on AIM at 8.00 am tomorrow, comprising the 6,315,790 shares issued in relation to the placing and the 737,595 shares issued in relation to the exercise of options by certain directors and employees of the Company. The resulting shareholdings of the directors, following admission of the new ordinary shares, are set out in the table below:

Name			Holding after exercise and sale			Percentage holding after exercise and sale of new shares*
Peter Lawrence			11,373,176			18.22%
Brett Clemo			436,948			0.70%
Marc Loomes			1,131,110			1.82%
Kevin Stockdale			370,411			0.60%
Julia Trouse			518,605			0.83%

*The vast majority of the shares (2,424,290) in which the Directors (apart from Peter Lawrence) have a beneficial interest are held jointly by the ECO Animal Health Group Employee Benefit Trust and the Director concerned, under the terms of a Joint Share Ownership Plan. These shares do not hold voting rights.

Following the issue of the new ordinary shares the Company’s total issued share capital with voting rights and which is admitted to trading on AIM consists of 62,429,391 ordinary shares of 5p each, with one voting right per share.

Enquiries:

	ECO Animal Health Group plc
	Peter Lawrence, Executive Chairman			020 8336 6190
	Marc Loomes, CEO			020 8447 8899
	Spiro Financial
	Anthony Spiro			020 8336 6196
	Cenkos Securities plc (Nominated Adviser)
	Stephen Keys			020 7397 8926
	Elizabeth Bowman			020 7397 8928

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.